Sanofi filings document a foreign biopharmaceutical issuer whose American depositary shares represent interests in ordinary shares. Its SEC record includes Form 6-K reports and Form 20-F annual reporting that incorporate parent-company press releases, financial reports, governance materials and ADR-related disclosure.
Sanofi’s filings cover operating results, research and development spending, product and pipeline updates, regulatory approvals and designations, and therapeutic areas such as immunology, vaccines, rare diseases, oncology, respiratory disease and diabetes. They also document bond issuance under its Euro Medium Term Note programme, share buyback activity, annual meeting resolutions, board and executive appointments, risk factors and capital-structure matters.
Sanofi (SNY) reported Q3 2026 net sales of €14.444 billion, up 14.3% at constant exchange rates (CER), and business EPS of €3.55, up 19.6% at CER; IFRS EPS was €2.52. Business operating income was €5.430 billion, up 19.7% at CER. Dupixent sales rose 34.8% to €5.687 billion, while vaccine sales declined 6.6% to €3.185 billion, mainly reflecting anticipated respiratory-prevention phasing.
Sanofi upgraded 2026 guidance to low-teens percentage sales growth and mid-teens percentage business EPS growth at CER. YTD 2026 free cash flow was €6.993 billion; net debt was €12.201 billion at September 30, 2026.
Sanofi and Regeneron announced an expanded collaboration under which they intend to co-develop and co-market four long-acting antibodies. Sanofi will pay $1 billion upfront, with potential development, regulatory and commercial milestone payments of up to an additional $7 billion; development and commercial costs will be shared, and future profits from the potential medicines split 50:50 globally. Separately, a planned transfer of 20 mature medicines and three manufacturing sites to Cheplapharm provides for a 26.4% equity stake in Cheplapharm for Sanofi, subject to employee consultation, regulatory approvals and customary closing conditions.
Sanofi (SNY) ownership figures reported by Amundi and Amundi Asset Management show beneficial ownership of 68,832,052 shares, or 5.70% of the class. Both report shared voting power over 34,587,207 shares and shared dispositive power over 34,244,845 shares; sole voting and dispositive power are zero. The two reports show the same position figures.
Amundi states it does not have voting rights over 30,319,386 shares held through an FCPE dedicated to Sanofi group employee shareholding. The FCPE supervisory board exercises the associated voting rights, with employee representatives holding a majority.
Sanofi broke ground on a new insulin manufacturing facility at its BioCampus in Frankfurt, Germany, on October 19, 2026. The facility will occupy a 36,000-square-meter footprint and is designed to use advanced digital technologies and artificial intelligence in manufacturing and quality processes.
Full production of insulin active pharmaceutical ingredient is planned for 2032, once the facility is fully licensed. Sanofi says its Frankfurt campus covers the insulin manufacturing value chain, with around 4,000 employees dedicated to insulin and approximately 20 insulin products supplied from the site. Sanofi currently supplies insulin to approximately 15 million people in more than 100 countries each year. In September 2026, the European Commission approved public support from the German Federal Government, the State of Hesse and the City of Frankfurt under the European Union’s state aid framework.
Sanofi expanded its global alliance with Regeneron to co-develop and co-commercialize four Regeneron-invented, long-acting antibodies targeting IL-13, IL-4xIL-13, IL-4 and IL-4Rα. Sanofi will pay Regeneron $1 billion upfront, with potential development, regulatory and commercial milestone payments of up to an additional $7 billion.
The companies will share development and commercialization costs and split future profits from the programs 50:50 globally. Regeneron will lead research and development, while Sanofi will lead global commercial efforts; the existing Dupixent profit-sharing agreement is unchanged. Regeneron also has an option to include Sanofi’s investigational lunsekimig, exercisable upon completion of its phase 3 studies for chronic obstructive pulmonary disease.
REGN20423, the IL-13 antibody, is in a phase 1 study for atopic dermatitis; the other three antibodies are expected to enter clinical studies in 2027. The companies said they have settled their prior collaboration-related litigation. More than 1.5 million people currently receive Dupixent across nine indications.
Sanofi (SNY) announced plans for a strategic partnership with Cheplapharm under which Cheplapharm would take over a portfolio of 20 mature medicines and three manufacturing sites worldwide. In exchange, Sanofi will receive a 26.4% equity stake in Cheplapharm, deepening a collaboration that began in 2014.
The sites in Csanyikvölgy (Hungary), Jurong (Singapore) and Ploërmel (France) would transfer with existing employment arrangements and collective agreements maintained. Commercial transfer of the medicine portfolio is planned to start in the first quarter of 2027, with full completion of the transaction expected by the third quarter of 2027, subject to employee consultations, regulatory approvals and customary closing conditions. Sanofi states the proposed transaction is not expected to affect its 2026 financial guidance.
Sanofi, through wholly owned subsidiaries, converted 782,855 shares of Attovia Therapeutics Series C preferred stock into 782,855 shares of common stock automatically upon Attovia’s IPO on August 6, 2026, and also purchased 300,000 common shares in the IPO at $17.00 per share. Following the IPO, Sanofi stated its beneficial ownership fell below 10% due to additional common shares issued.
Sanofi received European Commission approval to extend the indication of its MenQuadfi (MenACWY conjugate vaccine) to infants from six weeks of age across the EU, expanding use beyond the prior 12 months-and-older authorization to help protect against invasive meningococcal disease caused by serogroups A, C, W, and Y.
The decision is supported by the MET58 pivotal study on immunogenicity, safety, and tolerability in young infants and by a broader clinical program involving more than 6,000 infants in 11 countries. The vaccine’s safety and immunogenicity profile has been established from six weeks of age through adulthood and can be co-administered with several routine pediatric vaccines.
Sanofi filed an initial ownership report for its stake in Attovia Therapeutics, Inc. through indirect holdings of Series C preferred stock. Sanofi, as a more-than-10% owner, reports 782,855 shares of Series C preferred stock, representing 782,855 underlying shares of common stock held indirectly through wholly owned subsidiaries.
The Series C preferred stock is convertible at the holder’s option into common stock based on a $1.375 reference amount divided by a conversion price defined in Attovia’s Restated Certificate of Incorporation. The preferred shares may cease to be convertible upon certain redemptions, liquidations, dissolutions, or a winding up, and will convert automatically upon a Qualified Public Offering or at the Mandatory Conversion Time, as described in that certificate.
Sanofi reported first-half 2026 net sales of €22,106 million, up from €19,889 million a year earlier, with strong contributions including Dupixent net sales of €9,324 million. Total net income was €1,997 million versus €5,837 million, reflecting lower discontinued-operation gains and higher charges.
Results were weighed by €1,031 million of intangible asset impairments, mainly a €952 million write-down of amlitelimab, and a higher effective tax rate of 30.6%. Operating cash flow rose to €4,643 million, while a cash tender offer for Dynavax (purchase price €1,571 million, net outflow €1,403 million), dividends of €4,923 million and share buybacks of €1,003 million contributed to an increase in net debt to €15,513 million from €11,008 million. Sanofi also classified its Brazilian generics unit Medley as held for sale, expecting a net gain on closing, subject to regulatory clearance.
Sanofi reported Q2 2026 net sales of €11,597 million, up 17.8% at constant exchange rates and 16.0% at actual rates. Business EPS was €2.09, up 33.3% at constant exchange rates, driven by strong growth in pharma launches (€1,305 million, +48.3%) and Dupixent (€5,154 million, +37.6%). Vaccines declined 4.7% to €1,150 million. IFRS EPS was €0.29, down 91.0%, including an impairment expense of €1,031 million, mainly €952 million related to the amlitelimab intangible asset.
Business operating income reached €3,291 million, up 35.8% at constant exchange rates, with a margin of 28.4%. H1 2026 free cash flow was €3,724 million, up 51.5%. A €1 billion share buyback was completed and the 2025 dividend of €4.12 per share was approved. Net debt rose to €15,513 million from €10,988 million as of January 1, 2026, reflecting the Dynavax acquisition, dividends and the buyback.
The company recorded seven regulatory approvals across immunology, rare diseases, oncology and neurology, including new indications or formulations for Dupixent, Tzield, Wayrilz, Sarclisa and Cenrifki, plus multiple priority and fast-track designations. Strategic pipeline decisions led to discontinuation of amlitelimab, itepekimab and balinatunfib programmes. The Impact medicines portfolio now reaches 30 underserved countries, and the Global Health Unit has treated 195,263 non-communicable disease patients cumulatively since 2022.